Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Glaukos

Intuitive Surgical

Nevro

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Prestige Brands Holdings

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

PBH or SYK: Which Is the Better Value Stock Right Now?

Abbott Labs

Amgen

Boston Scientific

Salesforce

Gilead Sciences

Goldman Sachs

Intuit

Medtronic

Tesla

Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.

The Best Large-Cap Stocks to Buy

SYK launches the Oculan Lighting Platform to improve lighting conditions in the operating rooms and allow surgeons to perform with more accuracy.

Stryker Stock May Gain From Oculan Lighting Platform's Launch

Strong financial performance has investors eyeing Stryker Corporation (SYK) closely.

Stryker Bringing in Big Money

FLOWER MOUND, Texas, USA, Nov. 19, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons to focus on delivering the highest standard of care. In today's operating rooms, where precision and accuracy are critical, even the smallest challenges may impact surgical outcomes – factors which may impede a surgeon's ability to see clearly and work efficiently.

Stryker unveils Oculan Lighting Platform to enhance surgical visualization and illumination

Stryker launches the next generation of SurgiCount+ to boost sponge management and blood loss assessment in hospitals.

SYK Stock Rises Following the Launch of Next Generation SurgiCount+

PORTAGE, Mich., USA, Nov. 14, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio.

Stryker launches next generation of SurgiCount+ to help improve the standard of care in hospitals for sponge management and blood loss assessment

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

PBH vs. SYK: Which Stock Is the Better Value Option?

BellRing Brands Inc

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.

Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance

Stryker Corporation. (NYSE:SYK ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Securities Joanne Wuensch - Citi Ryan Zimmerman - BTIG Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Companies Vijay Kumar - Evercore ISI Matthew Miksic - Barclays Steven Litchman - Oppenheimer & Co David Roman - Goldman Sachs Christopher Pasquale - Nephron Research Jason Wittes - Roth MKM Michael Matson - Needham & Company Danielle Antalffy - UBS Equities Richard Newitter - Truist Securities Matthew Taylor - Jefferies Jeffrey Johnson - Robert W.

Stryker Corporation (SYK) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Stryker (SYK) Q3 Earnings

Stryker (SYK) came out with quarterly earnings of $2.87 per share, beating the Zacks Consensus Estimate of $2.78 per share. This compares to earnings of $2.46 per share a year ago.

Stryker (SYK) Surpasses Q3 Earnings and Revenue Estimates

SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Strong Segmental Performance to Drive Stryker's Q3 Earnings

Evaluate the expected performance of Stryker (SYK) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Insights Into Stryker (SYK) Q3: Wall Street Projections for Key Metrics

Stryker Corporation is a global leader in medical devices, with strong growth prospects driven by an aging population and technological advancements. SYK has a robust track record of double-digit earnings growth and high single-digit organic revenue growth, outperforming peers. Stryker's innovative products, like the Mako robot, and strategic acquisitions bolster its market position and future growth potential.

Stryker: A High Quality MedTech Name Investors Should Own

Stryker Corporation stock is recommended as a Buy due to its steady earnings growth, margin improvements, and strategic acquisitions, with a one-year price target 12.66% higher. Recent financial results show robust performance, with net sales up 8.5%, adjusted EPS up 10.6%, and a healthy balance sheet with reduced long-term debt. Stryker's growth prospects are supported by organic growth, acquisitions, and expanding margins, alongside a modest but growing dividend, making it an attractive stock for growth investors.

Stryker: More Earnings Growth And Higher Prices Ahead

Stryker SYK is a medical device company that has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry. The company has often acquired other firms to boost its competitiveness and add capabilities.

Stryker's Acquisition Spree: Double-Digit Growth on the Horizon

Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.

Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?

Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.

SYK Stock May Gain From Completion of Vertos Medical Acquisition

Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report its third quarter 2024 financial results on Tuesday, October 29, 2024.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the quarter ended September 30, 2024.

Stryker to announce its third quarter 2024 financial results

Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis.

Stryker completes acquisition of Vertos Medical, Inc., expanding interventional pain management solutions

SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Reasons to Retain Stryker Stock in Your Portfolio for Now

SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.

News for Stryker Stock (SYK)